<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02153593</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-EVI-2011-138</org_study_id>
    <secondary_id>EC11-340</secondary_id>
    <secondary_id>2011-006276-40</secondary_id>
    <nct_id>NCT02153593</nct_id>
  </id_info>
  <brief_title>Postoperative Bleeding Prevention in Massive Bone Tumour Resection</brief_title>
  <acronym>TRANEXTUM</acronym>
  <official_title>Postoperative Bleeding Prevention in Massive Bone Tumour Resection: a Multicentric, Randomized, Parallel, Controlled Trial to Assess the Efficacy of Tranexamic Acid Versus Evicel® and Usual Haemostasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Massive bone tumour resection is often associated with important postoperative bleeding. This
      may determine systemic (anaemia), as well as local complications (wound healing, seroma,
      haematoma).

      The objective of this study is to determine whether the use of topical tranexamic acid or
      topical Evicel® will reduce the perioperative bleeding comparing it with usual haemostasis.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty in recruitment
  </why_stopped>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total blood loss (mL) in the postoperative period</measure>
    <time_frame>The first postoperative 48h</time_frame>
    <description>The blood loss will be collected by the drainage system and quantified in mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring blood transfusion</measure>
    <time_frame>The first postoperative 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Units of blood transfused</measure>
    <time_frame>The first postoperative 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with wound infection</measure>
    <time_frame>The first postoperative month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with wound dehiscence</measure>
    <time_frame>The first postoperative month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with reoperation for wound complications</measure>
    <time_frame>The first postoperative month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deep venous thrombosis</measure>
    <time_frame>The first postoperative 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with seroma</measure>
    <time_frame>The first postoperative month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain related with the surgery</measure>
    <time_frame>The first postoperative week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumoral local relapse rate</measure>
    <time_frame>The first postoperative month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumoral systemic dissemination rate</measure>
    <time_frame>The first postoperative month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>The first postoperative month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in which chemotherapy is delayed for wound complications</measure>
    <time_frame>The first postoperative month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in which radiotherapy is delayed for wound complications.</measure>
    <time_frame>The first postoperative month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>The first postoperative 2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Blood Loss</condition>
  <condition>Bone Tumour</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tranexamic acid, 1g intra-articular before closing the surgery wound</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fibrin glue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One intra-articular dose of fibrin glue (Evicel 5mL) before closing the wound surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual hemostasia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Electrocauterization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>1g intra-articular before closing the wound surgery</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <other_name>Amchafibrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fibrin glue</intervention_name>
    <description>5mL intra-articular before closing the wound surgery</description>
    <arm_group_label>Fibrin glue</arm_group_label>
    <other_name>Evicel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electrocauterization</intervention_name>
    <description>Coagulation blood from vessels by means of a electrocautery</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_label>Fibrin glue</arm_group_label>
    <arm_group_label>Usual hemostasia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years and older

          -  Musculoskeletal tumor (primary or metastatic, benign or malignant) located in
             extremities, shoulder girdle or pelvis.

          -  Massive or bloc tumour resection.

          -  Patient's consent to participate

        Exclusion Criteria:

          -  Known allergy to ATX

          -  Allergy or known hypersensitivity to bovine proteins (aprotinin)

          -  Liposarcomas low grade

          -  History of thromboembolic disease or prothrombotic conditions:

               -  cerebral vascular accident

               -  ischemic heart disease

               -  deep and / or superficial vein thrombosis

               -  pulmonary embolism

               -  peripheral arterial vasculopathy

               -  thrombogenic arrhythmias (eg: ACxFA)

               -  patients with cardiovascular stents

               -  prothrombotic alterations in coagulation

          -  Treatment with contraceptive drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Peiró, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario de Cruces</name>
      <address>
        <city>Barakaldo,</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de San Juan de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Ibáñez AP, Martinez-Zapata MJ, Tarragó LT, Balaguer MB, Roig XA, Joy IG, Areizaga L, Merino J, Alcalá R, Tranextum Study Group. Postoperative bleeding prevention in massive bone tumour resection: a multicentric, randomized, parallel, controlled trial to assess the efficacy of tranexamic acid versus Evicel and usual haemostasis [protocol]. Basic and Clinical Pharmacology. 2014; 115 (Suppl 3): 20-21.</citation>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2014</study_first_submitted>
  <study_first_submitted_qc>June 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2014</study_first_posted>
  <last_update_submitted>September 19, 2016</last_update_submitted>
  <last_update_submitted_qc>September 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clinical trial</keyword>
  <keyword>Randomized</keyword>
  <keyword>Fibrin glue</keyword>
  <keyword>Tranexamic acid</keyword>
  <keyword>Blood loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

